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DOI 10.1186/s13148-015-0066-4RESEARCH Open AccessRARβ2 hypermethylation is associated with poor
recurrence-free survival in never-smokers with
adenocarcinoma of the lung
Yujin Kim1†, DongHao Jin1†, Bo Bin Lee1, Eun Yoon Cho2, Joungho Han2, Young Mog Shim3 and Duk-Hwan Kim1,4*Abstract
Background: This study was aimed at investigating if the effect of RARβ2 hypermethylation on recurrence-free survival
(RFS) in non-small cell lung cancer (NSCLC) depends on one’s smoking status and specific interacting proteins.
Results: We retrospectively analyzed the expressions of five proteins using immunohistochemistry in archival
formalin-fixed and paraffin-embedded tissues from 578 NSCLC patients who had undergone surgical resection
from 1994 through 2004. Promoter methylation of RARβ2 was assessed by bisulfite pyrosequencing. Recurrence
was found in 268 (46%) of 578 NSCLCs with a median follow-up period of 4.8 years. Overexpression of β-catenin, c-MET,
cyclin D1, and EGFR occurred in 55%, 72%, 51%, and 41% of the patients, respectively. E-cadherin expression was
negative in 62% of the patients, and RARβ2 hypermethylation was found in 37%. The abnormal expression of c-MET
(P = 0.002) and EGFR (P = 0.001) was found to be highly prevalent in never-smokers. RARβ2 hypermethylation was
significantly associated with poor recurrence-free survival (RFS) in 128 never-smokers with adenocarcinoma (P = 0.01)
For parsimonious model building, the five proteins were clustered into three groups (β-catenin and E-cadherin; c-MET;
cyclin D1 and EGFR) by an unsupervised hierarchical clustering and were included in a multivariate analysis. Cox
proportional hazard analysis showed that RARβ2 hypermethylation was significantly associated with poor RFS in
128 never-smokers with adenocarcinoma (adjusted hazard ratio [HR] = 2.19, 95% confidence interval [CI] = 1.28
to 3.47; P = 0.009), after adjusting for interacting proteins.
Conclusions: The present study suggests that RARβ2 hypermethylation may be an independent prognostic
factor of RFS in never-smokers with adenocarcinoma of the lung.
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Despite significant advances in diagnosis and treatment
over the past two decades, lung cancer is the leading
cause of cancer-related death in the world, and the over-
all five-year survival rate remains under 15% [1,2]. The
poor prognosis of lung cancer is partially due to the high
rate of recurrence after surgical resection. Given that
some patients may benefit from postoperative adjuvant
therapy shortly after resection, the discovery of biomarkers* Correspondence: dukhwan.kim@samsung.com
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unless otherwise stated.for the identification of patients who are at a high risk of
recurrence has become increasingly important for novel
targeted therapy and for improving recurrence prevention.
In recent years, a number of genetic and epigenetic mole-
cules have been discovered for the purpose, and novel
therapeutic agents are being developed that target those
molecules.
Retinoic acid (RA) induces growth inhibition and apop-
tosis mainly by regulating gene expression through its
nuclear receptors, known as retinoic acid receptors
(RARs) and retinoid X receptors (RXRs). The receptors
bind to a retinoic acid response element (RARE), consist-
ing of two 5′-AGGTCA-3′ direct repeats of the consensus
half-site sequence 5′-AGGTCA-3′, in the promoter re-
gion of the target genes to initiate their transcription. Both
RAR and RXR receptors have three subtypes (α, β, and γ)is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological features (N = 578)
Variable Number (%)
Age (years)a 60 ± 11
Tumor size (cm)a 4.1 ± 2.4


































Adenoca, adenocarcinoma; Squamous, squamous cell carcinoma.
aValues indicate mean ± standard deviation.
bDifferentiation data are missing for 61 patients.
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inoic acid receptor beta (RARβ) is expressed primarily in
epithelial cells and plays a central role in mediating the
growth inhibition of different types of cancer cells by ret-
inoic acid. The loss and reduction of RARβ expression
have been reported in a large percentage of patients with
lung cancer. The human RARβ gene has four isoforms
(β1, β2, β3, and β4), and the β2 isoform is most abundant
among the isoforms. In addition, several studies have indi-
cated that RARβ2 is primarily responsible for limiting the
growth of lung cancer cells [3-5]. Indeed, expression of
RARβ2 in RARβ-negative lung cancer cells has been
shown to restore retinoic acid-induced growth inhibition
[3], and transgenic mice expressing antisense or other
constructs that down-regulate RARβ2 developed lung
cancer [4].
The aberrant methylation of CpG islands at a pro-
moter region of tumor suppressor genes is an epigenetic
change that induces the transcriptional silencing of a
gene. The RARβ2 promoter contains a CpG island in the
5′-untranslated region that is frequently methylated in
cancer cells. Abnormal hypermethylation of the RARβ2
CpG island has been found in approximately 40% of
non-small cell lung cancers (NSCLCs) and identified as
part of a mechanism by which RARβ2 expression is re-
pressed [6-8]. In contrast to many previous reports
about the tumor-suppressive effect of RARβ in lung can-
cer, Kurie et al. [9] reported a negative effect of RARβ
expression on overall survival of stage I NSCLC. We also
reported a protective effect of RARβ2 hypermethylation
on the development of second primary lung cancers
(SPLCs) in smokers with NSCLC [8]. Based on these re-
ports, we hypothesized that an effect of RARβ2 hyper-
methylation on the recurrence in NSCLC may differ
according to exposure to tobacco smoke.
Cyclin D1, β-catenin, and E-cadherin are known to
interact with RAR [10-18], and the altered expression of
EGFR is known to occur at a high prevalence in never-
smokers [19,20]. In an effort to investigate whether
RARβ2 hypermethylation contributes to the development
of recurrence in NSCLC according to statuses of smoking
and interacting proteins, we analyzed the methylation
status of RARβ2 and the expression statuses of cyclin
D1, E-cadherin, β-catenin, EGFR, and c-MET in 578
NSCLC patients.
Results
Correlation of expression levels among five proteins
differs according to smoking status
The clinicopathological features of the 578 participants
are summarized in Table 1. The expression of E-cadherin
was found to be negative in 62% of them. Of those, the
overexpression of β-catenin, c-MET, cyclin D1, and
EGFR occurred in 55%, 72%, 51%, and 41% of patients,respectively. The positive immunohistochemical stain-
ing for the five proteins is shown in Figure 1A. Before
analyzing if the effect of RARβ2 hypermethylation on
RFS in NSCLC was different according to smoking sta-
tus and the possible interacting proteins, we first com-
pared the prevalence of abnormal expression of five
Figure 1 Prevalence of altered expression of five proteins and their correlation according to smoking status. (A) The expression levels of
five proteins were analyzed using immunohistochemical staining. Representative examples of positive staining of the five proteins are shown in
adenocarcinoma (upper) and squamous cell carcinoma (lower) (×200). (B) The prevalence of altered expression of individual proteins was
compared according to smoking status. P values were based on Kruskal-Wallis test. (C, D) Correlation among the five proteins was analyzed using
Spearman’s correlation coefficient in (C) never-smokers and (D) ever-smokers. Magenta color indicates P < 0.05.
Kim et al. Clinical Epigenetics  (2015) 7:32 Page 3 of 10proteins among never-smokers, former-smokers, and
current-smokers (Figure 1B). The prevalence of abnor-
mal expression of β-catenin, cyclin D1, and E-cadherin
was not significantly different according to smoking sta-
tus, but the abnormal expression of c-MET (P = 0.002)
and EGFR (P = 0.001) was found at a high prevalence in
never-smokers compared to former- and current-smokers.
For the former- and current-smokers, the prevalence of
abnormal expression of the five proteins was similar, and
therefore, we divided the patients into never-smokers
and ever-smokers and analyzed the correlation of the
expression levels of the five proteins in never-smokers
(Figure 1C) and ever-smokers (Figure 1D). Expression
levels of β-catenin were significantly correlated with
those of E-cadherin in never-smokers (P = 0.02) and in
ever-smokers (P = 0.01). In contrast, expression levels
of cyclin D1 were significantly associated with those of
EGFR in ever-smokers (P = 0.004) but not in never-
smokers (P = 0.19). Based on these observations, it is
likely that molecular alterations of some proteins andprotein-protein interactions may differ between never-
smokers and ever-smokers in NSCLC.
The effect of RARβ2 hypermethylation on RFS in
never-smokers is different according to histology
Methylation levels of RARβ2 were quantitated in 578
formalin-fixed paraffin-embedded tissues using bisulfite
pyrosequencing (Figure 2A). To define RARβ2 hyperme-
thylation, we analyzed the methylation levels of RARβ2
using pyrosequencing in 62 normal formalin-fixed paraffin-
embedded lung tissues. RARβ2 hypermethylation was
defined as methylation levels greater than or equal to
10%, because the methylation levels of RARβ2 in normal
tissues ranged between 2% and 9%. Based on the criteria,
the methylation levels of RARβ2 showed a significant
difference between normal tissues and hypermethy-
lated tumor tissues (P < 0.0001; Figure 2B; Wilcoxon
rank-sum test). RARβ2 expression was measured using
quantitative reverse transcription PCR in fresh-frozen
tumors and matched normal tissues from 48 NSCLC
Figure 2 Quantitative pyrosequencing analysis of RARβ2 methylation. (A) Methylation levels of RARβ2 were quantitatively measured using
pyrosequencing. The pyrograms of RARβ2 show low levels of RARβ2 in unmethylated CpGs (upper) and high levels in methylated CpGs (lower).
(B) Methylation levels of RARβ2 were compared between 62 normal control tissues from formalin-fixed paraffin-embedded tissue and 214
hypermethylated tumor tissues (P < 0.0001; Wilcoxon rank-sum test). (C) To determine if RARβ2 hypermethylation is associated with transcriptional
silencing, RARβ2 mRNA levels normalized to GAPDH were compared between methylated (N = 14) and unmethylated (N = 34) fresh-frozen tissues. The
fold change in RARβ2 mRNA levels was significantly different between the two groups (P < 0.0001; Wilcoxon rank-sum test).
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The fold change in RARβ2 mRNA levels normalized to
GAPDH was compared between tumor tissues with and
without RARβ2 hypermethylation (Figure 2C). Fourteen
(29%) of 48 tumor tissues showed a higher methylation of
RARβ2 and very low mRNA levels. The fold change in
RARβ2 mRNA levels was significantly different between
the groups (P < 0.0001; Wilcoxon rank-sum test).
Two hundred and sixty-eight patients (46%) had devel-
oped a recurrence during a median follow-up of 57 months;
local recurrence in 18%, distant recurrence in 69%, and dis-
tant and local recurrence in 13%. To analyze the effect of
RARβ2 hypermethylation on RFS, data were stratified intoFigure 3 Kaplan-Meier survival curves. The effect of RARβ2 hypermethyl
(B) 427 ever-smokers, (C) 128 never-smokers with adenocarcinoma, and (D) 23
the absence and presence of RARβ2 hypermethylation, respectively. P values wtwo groups, never-smokers and ever-smokers. For 151
never-smokers, five-year RFS rates were significantly differ-
ent according to methylation status of RARβ2 (P = 0.007;
Figure 3A): 31% for patients with RARβ2 hypermethylation
and 52% for those without RARβ2 hypermethylation. For
the 427 ever-smokers, RARβ2 hypermethylation was not
associated with RFS (P = 0.98; Figure 3B).
Lung cancer histology is known to be associated with
smoking status: adenocarcinoma develops more fre-
quently in never-smokers, whereas other cell types are
more common in ever-smokers. This suggests that the
relationship between RFS and RARβ2 hypermethylation
in never-smokers may be confounded by a histologication on RFS was analyzed using a log-rank test in (A) 151 never-smokers,
never-smokers with other cell types. The minus and plus signs indicate
ere based on the log-rank test.
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types, and RFS in never-smokers were further analyzed
under this classification. For adenocarcinoma cases, five-year
RFS rates were 27% and 46% in patients with RARβ2
hypermethylation and in those without, respectively,
and this difference was statistically significant (P = 0.01;
Figure 3C). However, RFS in cases with other histologic
subtypes was not found to be significantly different be-
tween patients with and without RARβ2 hypermethylation
(P = 0.28; Figure 3D).
No heterogeneity of association between RARβ2
hypermethylation and recurrence across the proteins
To adjust for effect modifiers or confounding factors in
the relationship between RARβ2 hypermethylation and
RFS in never-smokers with adenocarcinoma, we evaluated
if the population odds ratios between RARβ2 hypermethy-
lation and the risk of recurrence were uniform across the
altered expression of individual proteins in never-smokers
with adenocarcinoma. The Breslow-Day test for homogen-
eity of the odds ratio showed no evidence of heterogeneity
in cases of RARβ2 hypermethylation across the altered ex-
pression of β-catenin (P = 0.18), c-MET (P = 0.48), cyclin
D1 (P = 0.27), E-cadherin (P = 0.95), and EGFR (P = 0.68).
The altered expression of individual proteins might
not be an effect modifier in the relationship between
RARβ2 hypermethylation and recurrence in our popu-
lation. Therefore, we did not construct various contin-
gency tables as if they had been drawn from distinct
populations and computed a single summary measure
rather than individual hazard ratio across the proteins
for the 128 cases.
No association between RARβ2 hypermethylation and
protein expression levels
The five proteins analyzed in this study were considered as
potential confounding factors in the relationship of RARβ2
hypermethylation with RFS, since cyclin D1, β-catenin,
and E-cadherin are known to interact with retinoid sig-
naling. To evaluate if altered expression of individual pro-
teins can be confounding variables in never-smokers with
adenocarcinoma, we analyzed its association with RARβ2
hypermethylation. Composite scores of individual proteins
in never-smokers with adenocarcinoma were compared
according to methylation status of RARβ2 (Figure 4A).
However, RARβ2 hypermethylation was not associated
with the composite scores of β-catenin (P = 0.65; Wilcoxon
rank-sum test), c-MET (P = 0.30), cyclin D1 (P = 0.38),
E-cadherin (P = 0.21), or EGFR (P = 0.07), suggesting that
there may be no interaction between RARβ2 and the five
proteins in never-smokers with adenocarcinoma. Next,
the univariate Cox proportional hazard model was applied
to assess the independent effects of the five proteins on
RFS in 128 never-smokers with adenocarcinoma. Tumorsize, sex, histology, pathologic stage, and RARβ2 hyperme-
thylation showed a statistically significant association with
RFS, but none of the individual proteins showed a signifi-
cant association with RFS (Table 2).
Multivariate Cox proportional hazards analysis of RFS
Finally, multivariate Cox proportional hazards analysis
for 128 never-smokers with adenocarcinoma was performed
to determine whether RARβ2 hypermethylation was an
independent prognostic factor for RFS, after control-
ling for the potential confounding effects of variables.
The expression levels of the five proteins were not sta-
tistically associated with RFS in the 128 never-smokers
with adenocarcinoma. However, given that retinoid signal-
ing interacts with the proteins biologically, the proteins
were included in the multivariate analysis. For more parsi-
monious model building, a data mining for the five pro-
teins was conducted using an unsupervised hierarchical
clustering and a heatmap showed the expression patterns
of the five proteins (Figure 4B). The β-catenin was close to
E-cadherin, and cyclin D1 was close to EGFR. The data
were partitioned into three clusters (β-catenin/E-cadherin,
c-MET, and cyclin D1/EGFR) and included in the multi-
variate analysis. A Cox proportional hazard model showed
that RFS in 128 never-smokers with adenocarcinoma
was found to be 2.19 times (95% confidence interval
[CI] = 1.28 to 3.47; P = 0.009; Table 3) poorer than that
in those without RARβ2 hypermethylation. However,
no protein clusters were associated with RFS.
Discussion
Several studies have suggested that retinoids may have
harmful effects in the prevention of lung cancer. However,
most studies about the tertiary chemopreventive effect of
retinoids in surgically treated lung cancer have focused
primarily on smokers, and relatively few studies have
examined the chemopreventive effect of retinoids in
never-smokers. Although tobacco smoking accounts
for the majority of lung cancer as a presumed etiology,
it is estimated that 15% of male and 53% of female lung
cancer patients are lifelong never-smokers worldwide [21].
More and more studies have suggested that lung cancers
occurring in never-smokers may be a distinctive disease
due to unique molecular profiles [22-25]. To understand
the effect of RARβ2 hypermethylation on recurrence ac-
cording to smoking status in NSCLC, we analyzed RARβ2
hypermethylation and expression levels of five proteins in
584 NSCLCs. The proteins were adjusted as confounding
factors in the relationship of RARβ2 hypermethylation
with recurrence.
Among the five proteins analyzed in this study, β-catenin
and E-cadherin are known to interact with RAR [10-16].
β-catenin is a protein associated with the cytoplasmic
tail of E-cadherin, and the level of β-catenin in the
Figure 4 Unsupervised clustering of protein expression in 128 never-smokers with adenocarcinoma. (A) Boxplots of composite scores of
each of the five proteins. Composite scores of the expression levels of the five proteins were compared according to methylation status of RARβ2.
Salmon and dark turquoise bars indicate groups with and without RARβ2 hypermethylation, respectively. Outliers are represented by black dots.
(B) The hierarchical clustering of the expression patterns of the five proteins is shown. The scaled composite score of individual proteins is
plotted in a red-green scale, with red indicating low expression and green indicating high expression. Each row represents individual tissues and
each column represents the five proteins. The color in each cell reflects the expression levels of individual proteins in the corresponding tissue.
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genes. Nuclear β-catenin interacts with the TCF/LEF
(T cell factor/lymphocyte enhancer factor) family of
transcription factors and induces the transcription of genesinvolved in cell proliferation and/or inhibition of apoptosis.
Thus, constitutive activation of β-catenin may be a critical
step in tumorigenesis among divergent types of cancers.
Retinoid signaling has been found to be a potent inhibitor
Table 2 Univariate Cox proportional hazards analysis of
RFS in never-smokers with adenocarcinoma (N = 128)
Variable HR (95% CI) P value
Age (years) 0.98 (0.95 to 1.04) 0.58
Size (cm) 1.25 (1.12 to 1.40) <0.0001
Sex 0.64 (0.40 to 0.97) 0.05
Differentiation 1.32 (0.97 to 1.75) 0.06
Pathologic stage 1.72 (1.41 to 2.08) <0.0001
RARβ2 1.71 (1.16 to 2.57) 0.008
EGFR 0.82 (0.54 to 1.24) 0.35
c-MET 0.77 (0.46 to 1.25) 0.28
β-catenin 1.09 (0.72 to 1.65) 0.72
E-cadherin 1.14 (0.73 to 1.78) 0.54
Cyclin D1 1.10 (0.74 to 1.63) 0.63
HR, hazard ratio; CI, confidence interval.
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cells [13], neuronal cells [14], bronchial epithelial cells [15],
and ES cells [16]. E-cadherin is also known to interact
with RARs. In breast cancer cells, RA up-regulates the
function of the invasion-suppressor complex E-cadherin/
catenin [10]. Cadherin expression and function are ne-
cessary to mediate the effects of RA on adhesion and
differentiation [13].
The interaction between retinoid signaling and cyclin
D1 has also been reported in a variety of cancer cells.
Retinoic acid triggers G1 cell cycle arrest through the
degradation of cyclin D1 via the ubiquitin-proteasome
pathway [17]. Ectopic expression of cyclin D1 sensitizes
ER-positive breast cancer cells to a retinoic acid-induced
mitochondrial death pathway [18]. The activity of the
cyclin D1 reporter was reduced in response to retinoic
acid in breast cancer cells independently of β-catenin/
TCF signaling [13]. However, in this study, the altered
expression of cyclin D1 was not associated with RARβ2
hypermethylation (Figure 3A) or recurrence. These ob-
servations suggest that interaction between RARβ2 sig-
naling and E-cadherin/β-catenin or cyclin D1 may beTable 3 Multivariate Cox proportional hazards analysisa of
RFS according to RARβ2 hypermethylation, stratified by
histology, in never-smokers
RARβ2 hypermethylation HR 95% CI P value
A. Adenocarcinoma No 1.00
(N= 128) Yes 2.19 1.28 to
3.47
0.009
B. Other cell types No 1.00
(N= 23) Yes 3.27 0.71 to
16.23
0.16
HR, hazard ratio; CI, confidence interval.
aAdjusted for age, sex, differentiation, tumor size, pathologic stage, histology,
adjuvant chemotherapy, and protein clusters [(β-catenin/E-cadherin), c-MET, and
(cyclin D1/EGFR)].different in never-smokers. In addition, RARβ2 hyperme-
thylation may affect RFS irrespective of an alteration of
interacting proteins in never-smokers.
In this study, RARβ2 hypermethylation was not associated
with expression levels of the five proteins (Figure 4A). We
further analyzed the association between RARβ2 expression
in 48 fresh-frozen tumor tissues and the expression of the
other five proteins (data not shown). Twenty-six (54%) of 48
tumor tissues were found to lose RARβ2 expression. No as-
sociation was found between RARβ2 expression and the ex-
pression of five proteins in the 48 samples. However, the
association showed a different pattern in samples stratified
by histology: RARβ2 expression showed a reciprocal rela-
tionship with EGFR expression in adenocarcinoma and with
c-MET expression in squamous cell carcinoma, suggesting
that RARβ2 may interact with EGFR or c-MET in a tissue-
dependent manner. Further study in a larger sample is
required to clearly understand the relationship between
RARβ2 and EGFR (or c-MET) according to histological
subtypes.
Mutations in the epidermal growth factor receptor
(EGFR) gene are more common in lung cancers from
never-smokers compared to ever-smokers in both men
and women. EGFR overexpression in this study was
found in 71 (47%) of 151 never-smokers and was more
frequent in adenocarcinoma (56%) than in squamous cell
carcinoma (34%); results which were consistent with
previous reports [19,20]. The c-MET is a proto-oncogene
that codes for a protein known as hepatocyte growth fac-
tor receptor (HGFR), which has tyrosine kinase activity. In
this study, overexpression of c-MET was found at a higher
prevalence in never-smokers compared to ever-smokers
(Figure 1B; P = 0.002). However, the altered expression of
β-catenin, cyclin D1, and E-cadherin occurred at a similar
frequency in never-smokers and ever-smokers. Based on
these observations, some of the molecular alterations in
never-smokers with NSCLC may be similar to those typic-
ally seen in lung cancer associated with tobacco smoking,
but separate and distinct molecular features seem to exist
in never-smokers.
EGFR overexpression in this study was not associated
with RFS in never-smokers with adenocarcinoma (Table 2).
To understand if EGFR mutations can affect RFS, we
sequenced the exons 18, 19, and 21 of EGFR in 48
fresh-frozen tumor tissues (data not shown). The deletion
in exon 19 or L858R missense mutation in exon 21 were
found in 17 (34%) of 48 tumor tissues. The effect of the
EGFR mutation on RFS was tested by Kaplan-Meier sur-
vival curve. Patients with an EGFR mutation showed a
trend toward poor RFS, though it was not statistically sig-
nificant (P = 0.08). The lack of an effect of the EGFR mu-
tation on RFS in this study may have resulted from the
small sample size or from the lack of targeted chemother-
apy of tyrosine kinase inhibitors. The effect of the EGFR
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warrants further study in a large prospective cohort.
Is it reasonable to recommend the intake of retinoids
for the chemoprevention of recurrence in never-smokers
who have undergone surgical resection for NSCLC? The
response to retinoic acid may be different according to a
patient’s exposure to tobacco smoke. A significant res-
toration of RARβ expression and reduction of metaplasia
were found in former-smokers treated with 9-cis-retinoic
acid [9]. Treatment of 9-cis-RA in former-smokers modu-
lated serum concentrations of insulin-like growth factor
(IGF)-I, IGF binding protein (IGFBP)-3, and their molar
ratio (IGF-I/IGFBP-3) [26]. In contrast to our previous
finding that the hypermethylation of RARβ2 gene in
current-smokers had a beneficial effect on the develop-
ment of SPLC in NSCLC (8), the present study suggests
that RARβ2 hypermethylation may be associated with
poor RFS in never-smokers with adenocarcinoma. Taken
together, the combination of retinoic acid and the
demethylating agent is recommended for the preven-
tion of recurrence irrespective of alteration of the five pro-
teins in never-smokers with adenocarcinoma. In addition,
retinoic acid may be beneficial for the primary prevention
of lung cancer in never-smokers with high risk factors,
such as particular genetic mutations predisposing them to
cancer development and for the secondary prevention of
disease progression in never-smokers with premalignant
lesions.
This study was severely limited by several factors.
First, the number of cases with other cell types rather
than adenocarcinoma was very small. For the application
of retinoic acid in a clinical practice, the effect of RARβ2
hypermethylation on RFS in never-smokers with adeno-
carcinoma as well as other cell types should be further
validated by prospective large-scale studies. Second, the
molecular mechanisms underlying the finding that RARβ2
hypermethylation contributes to poor RFS in never-smokers
with adenocarcinoma should be studied. Third, other pro-
teins interacting with RAR that were not analyzed in this
study also need to be analyzed to clearly understand the ef-
fect of retinoic acid on RFS in never-smokers.
Conclusions
RARβ2 hypermethylation is known to occur in approxi-
mately 40% of NSCLCs. The present study suggests that
RARβ2 hypermethylation may be associated with poor
RFS in never-smokers with adenocarcinoma.
Methods
Study population
A total of 578 formalin-fixed paraffin-embedded (FFPE)
tissues were obtained from NSCLC patients undergoing
surgical resection between May 1994 and September 2004
at the Samsung Medical Center in Seoul, Korea. Themedian duration of follow-up was 57 months. A written
informed consent was obtained from the patients before
surgery. This study was approved by the Samsung Medical
Center (SMC) Institutional Review Board (IRB). Post-
operative follow-up for the detection of local and distant
recurrence was performed as previously described [2,8],
and recurrence was evaluated from information obtained
from our hospital’s electronic medical records and those
from other hospitals, as of November 2013. All cases of
cancer were classified based on the guidelines of the
tumor-node-metastasis (TNM) staging system of the
American Joint Committee on Cancer [27]. Never-smoker
was defined as a person who has never smoked or who
has smoked fewer than 100 cigarettes in his or her
lifetime.
Immunohistochemistry
Tissue microarrays (TMAs) of NSCLCs and immunohis-
tochemical staining of the five proteins were conducted
as previously described [28]. The sections were incubated
overnight at 4°C with the following primary antibodies:
β-catenin (clone 17C2; Novocastra, Buckinghamshire,
UK) at 1:100 dilution, c-MET (3D4, Zymed, South San
Francisco, CA, USA) at 1:200 dilution, cyclin D1 (SP4,
Lab Vision, Fremont, CA, USA) at 1:50 dilution, E-cadherin
(4A2C7, Zymed, South San Francisco, CA) at 1:100 dilution,
or EGFR (1005, Santa Cruz, CA, USA) at 1:100 dilution.
Detection of immunoreactivity by each antibody was
performed by EnvisionTM+ peroxidase (Dako, Carpinteria,
CA, USA). The peroxidase activity for each antibody
was visualized by applying diaminobenzidine chromo-
gen containing 0.05% hydrogen peroxide for 3 to
8 min at room temperature. Nuclei were then coun-
terstained with Mayer’s hematoxylin, and negative
controls were included in each run by omitting the
primary antibody.
Interpretation of immunohistochemical staining
The slides were read by two authors (EYC, JH), who
were blinded to the clinical outcome of the patients, to
reduce inter-observer variability. The correlation of scores
between the two readers of immunohistochemical staining
was calculated, and samples showing kappa values less
than 0.20, poor inter-rater reliability, were removed from
further analysis. Cyclin D1 was stained in the cytoplasm
and nucleus, but only nuclear staining of cancer cells was
considered positive. The immunoreactivity of EGFR and
E-cadherin was found mainly in the membrane of neo-
plastic cells, and membrane staining was considered in
scoring. The c-MET is localized in both the cell membrane
and cytoplasm of cancer cells, and immunoreactivity in the
cytoplasm and membrane was semi-quantitatively graded
by considering the intensity of staining. Immunoreactivity
for β-catenin was observed in the membrane, cytoplasm,
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staining cells only in the cytoplasm were evaluated for
scoring.
The expression levels of five proteins were calculated
by multiplying the intensity score (0, none; 1, weak; 2,
moderate; 3, strong) and the proportion score of positive
staining tumor cells (0, absent; 1, 0% to 10%; 2, 10% to
50%; 3, 50% to 80%; 4, >80%). Cutoff values of the com-
posite scores for abnormal expression were determined
by using an internal control consisting of 62 normal lung
cores from 152 lung cancer blocks. To determine the
cutoffs for abnormal expression of individual protein, we
first analyzed the distribution of the composite scores
for abnormal expression of β-catenin, cyclin D1, EGFR,
E-cadherin, and c-MET proteins between the normal
and tumor tissues. Based on the distribution, we set sev-
eral cutoffs, compared false positives and false negatives
at different cutoffs, and finally determined the cutoffs of
the composite score that minimized false positives and
false negatives. The β-catenin, c-MET, cyclin D1, and
EGFR were considered to be overexpressed if the com-
posite score was greater than or equal to 2. E-cadherin
was defined as negative if the composite score of mem-
brane staining was less than 2.
Pyrosequencing
To microdissect tumor areas, we cut formalin-fixed,
paraffin-embedded tissues into 10-μm-thick sections. Before
DNA extraction, we performed hematoxylin-eosin staining
to locate the tumor areas and microdissected areas contain-
ing at least 75% neoplastic tissue. Five hundred nanograms
of genomic DNA was purified using the DNeasy Blood &
Tissue Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol and then bisulfite-converted
using the EZ DNA methylation kit (Zymo Research, Irvine,
CA, USA). The methylation levels of CpG islands at the P2
promoter region of the RARβ2 gene were analyzed by
pyrosequencing of bisulfite-treated DNA, as previously
described by Lee et al. [29]. Pyrosequencing was car-
ried out on a PSQ 96MD system with the PyroMark
PCR kit (Cat. No. 978703, Qiagen), and data were ana-
lyzed using the Q-CpG software (v.1.0.9, Pyrosequencing
AB, Uppsala, Sweden).
Quantitative reverse transcription-PCR (qRT-PCR)
The expression of RARβ2 was measured using TaqMan
assays following the manufacturer’s instructions on the
ABI 7500 Fast Real-Time PCR system (Applied Biosys-
tems, Waltham, MA, USA). One microgram of total
RNA was reverse transcribed using the SuperScript VILO
cDNA synthesis kit (Cat. No. 11754-050, Invitrogen,
Carlsbad, CA, USA), and the resulting cDNA was used
for real-time PCR. The GAPDH was included as an in-
ternal reference for RARβ2 expression. TaqMan primersets (Hs00977141-mH for RARβ2 and Hs0275899_g1
for GAPDH) were purchased from Life Technologies.
TaqMan probe sequences for RARβ2 and GAPDH
were FAM-CCTGCCTGGACATCCTGATTCTTAG-MBG
(110 bp) and FAM-GACTCATGACCACAGTCCATGCC
AT-MBG (93 bp), respectively. RARβ2 expression values
were normalized to the reference by using the comparative
Ct method.Statistical analysis
In the univariate analysis, the t-test (or Wilcoxon rank-sum
test or Kruskal-Wallis test) was used for the analysis of con-
tinuous variables. Correlations among expression levels of
the five proteins were compared using Spearman’s rank
correlation coefficients. The prognostic significance of the
five proteins and RARβ2 on recurrence-free survival (RFS)
was assessed by Kaplan-Meier survival curves, and the sig-
nificance of the difference in RFS between two groups was
evaluated using the log-rank test. The hazard ratios of
independent factors for RFS were estimated by multi-
variate Cox proportional hazard regression analysis.
All statistical analyses were two sided with a 5% type I
error rate. Expression patterns of the five proteins were
recognized using an unsupervised hierarchical cluster
analysis.
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